A Phase III Study of WSD0922-FU Versus Chemotherapy In Patients With C797S+ Advanced Non-small Cell Lung Cancer (WAYWIN-301)
An Open-label, Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of WSD0922-FU Monotherapy Versus Platinum-based Doublet Chemotherapy in Participants With EGFR C797S Mutation-positive, Locally Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Developed Resistance to Prior First-line Third-generation EGFR-TKI Therapy.
This is an Open-label, Randomized, Controlled, Multicenter Phase III Study Evaluating Efficacy and Safety of WSD0922-FU Monotherapy versus Platinum-based Doublet Chemotherapy for Participants with EGFR C797S Mutation-positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease have Developed Resistance to Prior First-line Third-generation EGFR-TKI Therapy
研究概览
地位
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Wei Zhong, PhD
- 电话号码:1-951-547-4692
- 邮箱:wei.zhong@wayshinebiopharm.com
研究联系人备份
- 姓名:Lily Liu, MD
- 电话号码:+8613818880308
- 邮箱:lily.liu@wayshinebiopharm.com
学习地点
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200123
- Shanghai East Hospital
-
接触:
- Fei Zhou, MD
- 电话号码:+86 21-38804518
- 邮箱:fei.zhou@tongji.edu.cn
-
首席研究员:
- Caicun Zhou, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Histologically or cytologically confirmed locally advanced or metastatic NSCLC
- Eligible for platinum-based doublet chemotherapy
- Prior first-line treatment with monotherapy of third-generation EGFR-TKIs (osimertinib, Firmonertinib, Almonertinib, etc.) or third-generation EGFR-TKIs combined with anti-angiogenic drugs or Lazertinib combined with Amivantamab, confirmed by imaging evidence of disease progression, and no other systemic antitumor therapy was administered after progression
- Tissue sample confirmed C797S positive by central lab using NGS
- At least one measurable target lesion per RECIST v1.1 criteria
- ECOG 0-1
- Adequate organ function and bone marrow function
- Women should take appropriate contraceptive measures and should not breastfeed. If they have fertility, they must undergo a negative pregnancy test before starting medication
- Male participants should agree to the use of contraceptive measures
Exclusion Criteria:
- Presence of clear bypass tumor driver (e.g., KRAS activating mutations, Braf V600E, MET exon 14 skipping, HER2 mutations, RET fusion, ROS1 fusion etc.)
- Histological or phenotypic transformation
- Any severe or uncontrolled systemic disease
- ≥ Grade 2 toxicities per CTCAE v6.0 attributed to prior anti-tumor therapy except hearing loss, hair loss, and fatigue
- Participants with leptomeningeal, brainstem, or spinal cord metastases and/or spinal cord compression, as well as active brain metastases, increased intracranial pressure or associated risks (such as intracranial hemorrhage or intracranial infection), or symptomatic cerebral complications requiring urgent neurosurgical or pharmacological (e.g., mannitol) intervention
- A history of interstitial lung disease (ILD), drug-induced ILD, or non-infectious pneumonitis requiring steroid treatment; or suspected ILD or non-infectious pneumonitis that can't be ruled out by imaging at the time of screening
- Clinically significant cardiac abnormalities or severe/uncontrolled/active cardiovascular disease
- Significant clinical bleeding tendency or history of severe arterial/venous thromboembolic events
- Poorly controlled diabetes mellitus or hypertension
- History of other primary malignancies within two years
- Known active or suspected autoimmune diseases; or known active ocular diseases (such as active wet age-related macular degeneration, diabetic retinopathy with macular edema)
- Active infectious diseases (e.g., active HIV, HBV and HCV)
- Known alcohol or drug dependence
- Mental disorders or poor compliance
- The investigator believes that the subject has other reasons that make them unsuitable for participating in this clinical study
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:WSD0922-FU Tablet
|
Participants will take WSD0922-FU 120 mg BID under fasted condition, administered orally; treatment cycles are 21 days in duration, continuing until disease progression, occurrence of intolerable toxicity, withdrawal of informed consent, death, or fulfillment of other protocol-specified criteria for treatment discontinuation
其他名称:
|
|
有源比较器:Platinum-Based Doublet Chemotherapy
|
Participants will receive 4 cycles of standard platinum-based doublet chemotherapy (selected by the investigator based on participant's condition and tolerance): Option 1: Pemetrexed 500 mg/m² IV infusion + Cisplatin 75 mg/m² IV infusion on Day 1 of each 21-day cycle. Option 2: Pemetrexed 500 mg/m² IV infusion + Carboplatin AUC 5 IV infusion on Day 1 of each 21-day cycle. Followed by maintenace of Pemetrexed 500 mg/m² IV infusion until disease progression, occurrence of intolerable toxicity, withdrawal of informed consent, death, or fulfillment of other protocol-specified criteria for treatment discontinuation
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression Free Survival (PFS)
大体时间:From date of randomization until the date of BICR confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
PFS as assessed by Blinded independent Central Review (BICR) per RECIST 1.1 |
From date of randomization until the date of BICR confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Survival (OS)
大体时间:From the date of randomization to the date of death from any cause, assessed up to 36 months.
|
OS |
From the date of randomization to the date of death from any cause, assessed up to 36 months.
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
PFS as assessed by investigator per RECIST 1.1
大体时间:From date of randomization until the date of investigator confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
From date of randomization until the date of investigator confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
|
Objective Response Rate (ORR)
大体时间:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
ORR as assessed by investigator and BICR per RECIST 1.1 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Duration of Response (DOR)
大体时间:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
DoR by BICR and Investigator per RECIST 1.1 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Disease Control Rate (DCR)
大体时间:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
DCR by BICR and Investigator per RECIST 1.1 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Time to Disease Progression (TTP)
大体时间:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
TTP by BICR and Investigator per RECIST 1.1 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Time to Response (TTR)
大体时间:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
TTR by BICR and Investigator per RECIST 1.1 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial ORR (icORR)
大体时间:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icORR by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial PFS (icPFS)
大体时间:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icPFS by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial DOR (icDOR)
大体时间:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icDOR by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial DCR (icDCR)
大体时间:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icDCR by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial TTP (icTTP)
大体时间:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icTTP by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial TTR (icTTR)
大体时间:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icTTR by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
AE and SAE
大体时间:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
AE and SAE per CTCAE 6.0 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, Core 30
大体时间:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
Quality of life according to the EORTC QLQ-C30 test results from a minimum of 0 to a maximum of 100, where higher scores represent either a better or worse outcome depending on the specific subscale |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13
大体时间:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
Quality of life according to the EORTC QLQ-LC13 test results from a minimum of 0 to a maximum of 100, where higher scores indicate a worse outcome |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
合作者和调查者
调查人员
- 首席研究员:Caicun Zhou, MD、Shanghai East Hospital
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- WSD0922-301
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.